Abstract #0367

Hyperpolarized 13C-Pyruvate MRSI in Prediction of Response to Tyrosine Kinase Inhibition Therapy in Gastric Cancer

Shadi A Esfahani ¹, Cody Callahan², Nicholas M Rotile¹, Peter D Caravan ¹, Aaron K Grant ², and Yi-Fen Yen¹

¹Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA, United States, ²Department of Radiology, Beth Israel Deaconess Medical Center, Boston, MA, United States

Personalized treatment of gastric cancer remains a major challenge mainly due to lack of an optimal imaging method for detection of early response to treatment. We evaluated the role of Hyperpolarized [1-13C] Pyruvate Magnetic Resonance Spectroscopic Imaging (HP-13C MRSI) for quantitative measurement of early changes in glycolytic metabolism of gastric cancer models upon initiation of afatinib, a pan-receptor tyrosine kinase inhibitor. We showed that HP-13C MRSI is more sensitive for detection of early metabolic changes in gastric cancer after starting treatment with afatinib compared to 18F-FDG PET/MRI, and therefore can be used for early prediction of response to targeted therapies.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.